Presbyopia Opportunity Orasis focuses on presbyopia with their Qlosi eye drop, indicating a direct upsell path to ophthalmology practices treating age-related blurry near vision. Buyers include eye care professionals seeking novel corrective solutions for adults, suggesting opportunity to expand into clinics, optometry chains, and surgical centers needing alternative presbyopia therapies.

Launch Readiness Recent Series D funding and a first fill free program signal strong market launch momentum and patient access initiatives. Leverage this to position distributors and clinics for quick onboarding, co-promotion, and in-office dispensing where permitted to accelerate adoption.

Quality & Ops Growth Key hires in quality and operations along with a growing commercial leadership team indicate scale-up in manufacturing, quality assurance, and supply chain. Target partnerships with contract manufacturers, quality-assurance collaborators, and distributors that benefit from robust regulatory and distribution capabilities.

Commercial Expansion A dedicated vice president of sales and a focus on in-office dispensing in select states suggests opportunities to partner with optometry networks, independent eye care practices, and regional distributors to expand geographic reach and patient access to Qlosi and related products.

Financial Health Substantial funding combined with a multi-year revenue trajectory positions Orasis as a growing late-stage biotech-like pharma player. Approach potential larger partners or strategic investors for co-development, regional regulatory support, or co-promotion agreements to extend market penetration.